Moleculin Announces Reverse Stock Split

Rhea-AI Summary

Moleculin (Nasdaq: MBRX) filed an amendment to its certificate of incorporation to effect a 1-for-25 reverse stock split of its common stock, effective 12:01 am ET on December 1, 2025. The company said shares will open for trading on Nasdaq on December 1, 2025 on a post-split basis under the existing ticker MBRX but with a new CUSIP 60855D 408. Every 25 pre-split shares will be consolidated into one share, with no change to the $0.001 par value. Fractional shares will not be issued; holders entitled to fractions will receive a cash payment in lieu. Outstanding shares are expected to fall from approximately 51.7 million to approximately 2.1 million, while authorized shares remain 500 million.

Positive

• Reverse split effective Dec 1, 2025 12:01 am ET
• Outstanding shares reduced from 51.7M to ~2.1M
• Post-split trading to continue under ticker MBRX

Negative

• New CUSIP assigned: 60855D 408
• Fractional holders to receive cash payment instead of shares
• Authorized shares remain at 500M, enabling future issuance

News Market Reaction

-22.03% 1.6x vol

23 alerts

-22.03% News Effect

-32.6% Trough in 2 hr 5 min

-$5M Valuation Impact

$18M Market Cap

1.6x Rel. Volume

On the day this news was published, MBRX declined 22.03%, reflecting a significant negative market reaction. Argus tracked a trough of -32.6% from its starting point during tracking. Our momentum scanner triggered 23 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $5M from the company's valuation, bringing the market cap to $18M at that time. Trading volume was above average at 1.6x the daily average, suggesting increased trading activity.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Reverse split ratio: 1-for-25 Effective time: 12:01 am ET Shares outstanding pre-split: 51.7 million shares +3 more

6 metrics

Reverse split ratio 1-for-25 Approved reverse stock split of common stock

Effective time 12:01 am ET Reverse split effective on December 1, 2025

Shares outstanding pre-split 51.7 million shares Common stock outstanding before reverse split

Shares outstanding post-split 2.1 million shares Common stock expected outstanding after reverse split

Authorized shares 500 million shares Authorized common shares remain unchanged

Par value per share $0.001 Nominal par value unchanged by reverse split

Market Reality Check

Price: $4.14 Vol: Volume 309,875 vs 20-day ...

normal vol

$4.14 Last Close

Volume Volume 309,875 vs 20-day average 287,102 (relative volume 1.08). normal

Technical Price $5 is trading below 200-day MA of $16.76 and 94.52% below 52-week high.

Peers on Argus

MBRX was down 27.15% while close peers showed mixed to positive moves (e.g., LPT...

MBRX was down 27.15% while close peers showed mixed to positive moves (e.g., LPTX up 238.84%, MBIO down 3.17%), suggesting a stock-specific reaction rather than a sector-wide move.

Historical Context

5 past events · Latest: Dec 10 (Negative)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 10	Warrant exercise financing	Negative	-27.1%	Agreements for immediate exercise of warrants for about $6.5M gross.
Dec 09	Clinical trial update	Positive	-8.6%	Reported progress and timelines for pivotal MIRACLE Phase 2B/3 AML trial.
Dec 08	Research collaboration	Positive	+0.1%	New Annamycin collaboration for GBM preclinical studies with CIC biomaGUNE.
Nov 26	Investor presentation	Neutral	-22.0%	Announcement of participation in Virtual Investor Closing Bell Series event.
Nov 26	Reverse stock split	Negative	-22.0%	Announcement of 1-for-25 reverse split reducing outstanding shares to ~2.1M.

Pattern Detected

Recent news shows heavy selling on financing and structural actions (offering, reverse split), while clinical and collaboration updates have seen more muted or diverging price responses.

Recent Company History

Over the last few weeks, Moleculin reported financing activity, clinical progress, collaborations, investor outreach, and this 1-for-25 reverse split. The Q3 10-Q highlighted losses and Nasdaq compliance issues, followed by insider equity awards and multiple 8-K disclosures. Financing news on Dec 10, 2025 and the reverse split announcement on Nov 26, 2025 coincided with sharp declines, while clinical and collaboration items around Annamycin drew smaller price moves. The reverse split fits into a broader picture of capital structure and listing-compliance challenges.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-09-19

The company has an active S-3 shelf registration filed on 2025-09-19, currently noted as not effective, with 0 recorded usages and an expiration on 2028-09-19. This provides a framework for potential future securities offerings if and when it becomes effective.

Market Pulse Summary

The stock dropped -22.0% in the session following this news. A negative reaction despite the mechani...

Analysis

The stock dropped -22.0% in the session following this news. A negative reaction despite the mechanical nature of a reverse split fits a pattern of sharp selloffs on structural and financing news, such as the prior warrant exercise transaction and this 1-for-25 split. The stock had already been trading 94.52% below its 52-week high, with outstanding shares moving from about 51.7 million to 2.1 million. An active but unused S-3 shelf and prior Nasdaq compliance issues add to perceived risk.

Key Terms

reverse stock split, nasdaq capital market, cusip, par value, +1 more

5 terms

reverse stock split financial

"to effect a 1-for-25 reverse stock split of its common stock."

A reverse stock split is when a company reduces the number of its shares outstanding, making each share more valuable. For example, if you own 100 shares worth $1 each, a 1-for-10 reverse split would turn your 100 shares into 10 shares worth $10 each. Companies often do this to boost their stock price and appear more stable to investors.

nasdaq capital market financial

"will open for trading on The Nasdaq Capital Market on December 1, 2025"

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

cusip financial

"under the existing ticker symbol “MBRX” but with a new CUSIP number 60855D 408."

A CUSIP is a nine-character alphanumeric code that uniquely identifies a U.S. or Canadian financial security—such as a stock, bond, or fund share—like a Social Security number for an investment. It matters to investors because brokers, exchanges and record-keepers use the CUSIP to match trades, track ownership, settle transactions and pull accurate records, reducing errors and ensuring money and securities go to the right place.

par value financial

"with no change in the nominal par value per share of $0.001."

Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.

fractional shares financial

"No fractional shares will be issued if, as a result of the reverse stock split,"

Fractional shares are portions of a whole share of a stock or fund, allowing investors to own less than one full unit. They make it possible to invest a specific dollar amount rather than buy whole shares, like buying a slice of a pizza instead of the entire pie. For investors this lowers the cost barrier, helps with diversification, and lets you reinvest dividends or purchase expensive stocks in small, precise amounts.

AI-generated analysis. Not financial advice.

HOUSTON, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that it filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-25 reverse stock split of its common stock. The reverse stock split will take effect at 12:01 am (Eastern Time) on December 1, 2025, and the Company’s common stock will open for trading on The Nasdaq Capital Market on December 1, 2025 on a post-split basis, under the existing ticker symbol “MBRX” but with a new CUSIP number 60855D 408.

As a result of the reverse stock split, every 25 shares of the Company’s common stock issued and outstanding prior to the opening of trading on December 1, 2025 will be consolidated into one issued and outstanding share, with no change in the nominal par value per share of $0.001. No fractional shares will be issued if, as a result of the reverse stock split, a stockholder would become entitled to a fractional share because the number of shares of common stock they hold before the reverse stock split is not evenly divisible by the split ratio. Instead, the stockholder will be entitled to receive a cash payment in lieu of a fractional share.

As a result of the reverse stock split, the number of shares of common stock outstanding will be reduced from approximately 51.7 million shares to approximately 2.1 million shares, and the number of authorized shares of common stock will remain at 500 million shares.

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company’s lead program, Annamycin, is a next-generation highly efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

The Company has begun the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC (the combination of Annamycin and cytarabine, also referred to as “Ara-C”) and, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.

Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin also has in its pipeline a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.

For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the timing and completion of the reverse split. Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the milestones described in this press release assume the Company’s ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin has attempted to identify forward-looking statements by terminology including ‘believes,’ ‘estimates,’ ‘anticipates,’ ‘expects,’ ‘plans,’ ‘projects,’ ‘intends,’ ‘potential,’ ‘may,’ ‘could,’ ‘might,’ ‘will,’ ‘should,’ ‘approximately’ or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. “Risk Factors” in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
MBRX@jtcir.com

FAQ

What is the reverse stock split ratio for Moleculin (MBRX) and when does it take effect?

Moleculin announced a 1-for-25 reverse stock split effective 12:01 am ET on December 1, 2025.

How many shares will Moleculin (MBRX) have outstanding after the reverse split?

Outstanding shares are expected to be reduced from approximately 51.7 million to approximately 2.1 million after the split.

Will Moleculin (MBRX) keep the same ticker after the reverse split?

Yes, Moleculin will continue trading under the existing ticker MBRX on Nasdaq on a post-split basis.

What happens to fractional shares after the MBRX 1-for-25 reverse split?

Fractional shares will not be issued; entitled holders will receive a cash payment in lieu of fractional shares.

Does Moleculin (MBRX) change its authorized share count after the reverse split?

No, the number of authorized shares remains at 500 million following the reverse split.

Will Moleculin (MBRX) have a new CUSIP after the reverse split?

Yes, the company will use a new CUSIP: 60855D 408 beginning December 1, 2025.